Respirably dry powder comprising calcium lactate, sodium chloride and leucine

Abstract

The present invention relates to respirable dry powders that contain respirable dry particles that comprise calcium lactate, sodium chloride, leucine, and one or more additional therapeutic agents; wherein the ratio of calcium cation to sodium cation is about 4:1 (mole:mole); and, wherein the calcium lactate is about 45.0% (w/w) to about 58.6% (w/w), and the sodium chloride is about 1.9% (w/w) to about 3.9% (w/w), where all weights are on a dry basis.

1 . A respirable dry powder, comprising: respirable dry particles that comprise calcium lactate, sodium chloride, leucine, and one or more additional therapeutic agents; wherein the ratio of calcium cation to sodium cation is about 4:1 (mole:mole); and, wherein the calcium lactate is about 45.0% (w/w) to about 58.6% (w/w), and the sodium chloride is about 1.9% (w/w) to about 3.9% (w/w), where all weights are on a dry basis. 
     
     
         2 . The respirable dry powder of  claim 1 , wherein the one or more additional therapeutic agents are selected from group consisting of corticosteroids and bronchodilators, and wherein said bronchodilators are one or more bronchodilators selected from the group consisting of long-acting beta 2  agonists and long-acting muscarinic anagonists. 
     
     
         3 . The respirable dry powder of  claim 2 , wherein said long-acting beta 2  agonists are selected from the group consisting of salmeterol, formoterol, arformoterol, clenbuterol, tulobuterol, vilanterol, indacaterol, carmoterol, isoproterenol, procaterol, bambuterol, and milveterol. 
     
     
         4 . The respirable dry powder of  claim 2 , wherein the long-acting muscarinic anagonists are selected from the group consisting of tiotroprium, trospium chloride, glycopyrrolate, aclidinium, and ipratropium. 
     
     
         5 . The respirable dry powder of  claim 2 , wherein the corticosteroids are selected from the group consisting of budesonide, fluticasone, flunisolide, triamcinolone, beclomethasone, mometasone, ciclesonide, and dexamethasone. 
     
     
         6 . The respirable dry powder of  claim 1 , wherein the one or more additional therapeutic agents is selected from the group consisting of bronchodilators, corticosteroids, and anti-inflammatory agents. 
     
     
         7 . The respirable dry powder of  claim 1 , wherein the one or more additional therapeutic agents is selected from the group consisting of mucoactive or mucolytic agents, surfactants, antibiotics, antivirals, antihistamines, cough suppressants, vaccines, adjuvants, and expectorants. 
     
     
         8 . The respirable dry powder of  claim 1 , wherein the one or more additional therapeutic agents is one or more macromolecules selected from the group consisting of proteins, large peptides, polysaccharides, oligosaccharides, DNA nucleic acid molecules and their analogs, and RNA nucleic acid molecules and their analogs. 
     
     
         9 . The respirable dry powder of  claim 8 , wherein the proteins are one or more antibodies. 
     
     
         10 . The respirable dry powder of  claim 9 , wherein the one or more antibodies are one or more monoclonal antibodies. 
     
     
         11 . The respirable dry powder of  claim 8 , wherein the macromolecule has a molecular weight of at least 800 Da. 
     
     
         12 . The respirable dry powder of  claim 1 , wherein said respirable dry particles have a volumetric median geometric diameter between 0.5 microns and 10 microns and a mass median aerodynamic diameter between 0.5 microns and 10 microns. 
     
     
         13 . The respirable dry powder of  claim 1 , wherein said respirable dry particles have a volumetric median geometric diameter between 1 micron and 5 microns and a mass median aerodynamic diameter between 1 micron and 5 microns. 
     
     
         14 . The respirable dry powder of  claim 13 , wherein said respirable dry powder is suitable for administration to a respiratory tract using a dry powder inhaler. 
     
     
         15 . The respirable dry powder of  claim 1 , wherein said respirable dry particles have a volumetric median geometric diameter of 5 microns or less and a mass median aerodynamic diameter of 5 microns or less. 
     
     
         16 . The respirable dry powder of  claim 15 , wherein said respirable dry powder is suitable for administration to a respiratory tract using a metered dose inhaler. 
     
     
         17 . The respirable dry powder of  claim 1 , wherein the leucine is about 27.5% (w/w) to about 37.5% (w/w). 
     
     
         18 . A method for treating a respiratory disease comprising administering to a respiratory tract of a patient in need thereof an effective amount of the respirable dry powder of  claim 1 . 
     
     
         19 . A method for treating or preventing an acute exacerbation of a respiratory disease comprising administering to a respiratory tract of a patient in need thereof an effective amount of the respirable dry powder of  claim 1 . 
     
     
         20 . A method for treating or preventing an infectious disease in a respiratory tract comprising administering to a respiratory tract of a patient in need thereof an effective amount of the respirable dry powder of  claim 1 .